Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

The lack of cytomegalovirus-specific cellular immune response may contribute to the onset of organ infection and disease in lung transplant recipients.

Costa C, Saldan A, Sinesi F, Sidoti F, Balloco C, Simeone S, Piceghello A, Mantovani S, Di Nauta A, Solidoro P, Cavallo R.

Int J Immunopathol Pharmacol. 2012 Oct-Dec;25(4):1003-9.

2.

Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.

Costa C, Astegiano S, Terlizzi ME, Sidoti F, Curtoni A, Solidoro P, Baldi S, Bergallo M, Cavallo R.

Transplant Proc. 2011 May;43(4):1159-61. doi: 10.1016/j.transproceed.2011.03.024.

PMID:
21620077
3.

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.

Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.

Transpl Infect Dis. 2012 Jun;14(3):248-58. doi: 10.1111/j.1399-3062.2012.00723.x. Epub 2012 Mar 5.

4.

Quantitative detection of human cytomegalovirus DNA in lung transplant recipients.

Kotsimbos AT, Sinickas V, Glare EM, Esmore DS, Snell GI, Walters EH, Williams TJ.

Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1241-6.

PMID:
9351628
5.

Increased human cytomegalovirus (HCMV) DNA load in peripheral blood leukocytes after lung transplantation correlates with HCMV pneumonitis.

Michaelides A, Liolios L, Glare EM, Spelman DW, Bailey MJ, Walters EH, Williams TJ, Snell GI, Kotsimbos TC.

Transplantation. 2001 Jul 15;72(1):141-7.

PMID:
11468549
6.

Human cytomegalovirus end-organ disease is associated with high or low systemic viral load in preemptively treated solid-organ transplant recipients.

Gerna G, Lilleri D, Furione M, Castiglioni B, Meloni F, Rampino T, Agozzino M, Arbustini E.

New Microbiol. 2012 Jul;35(3):279-87. Epub 2012 Jun 30.

7.

Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients.

Gerna G, Lilleri D, Rognoni V, Agozzino M, Meloni F, Oggionni T, Pellegrini C, Arbustini E, D'Armini AM.

Am J Transplant. 2009 May;9(5):1142-50. doi: 10.1111/j.1600-6143.2009.02616.x.

8.
9.

Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation.

Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, Pellegrini C, Meloni F, Rampino T.

Am J Transplant. 2006 Oct;6(10):2356-64. Epub 2006 Aug 1.

10.

Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.

Snyder LD, Medinas R, Chan C, Sparks S, Davis WA, Palmer SM, Weinhold KJ.

Am J Transplant. 2011 Mar;11(3):553-60. doi: 10.1111/j.1600-6143.2010.03405.x. Epub 2011 Jan 10.

11.

Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.

Baldanti F, Lilleri D, Campanini G, Comolli G, Ridolfo AL, Rusconi S, Gerna G.

J Antimicrob Chemother. 2004 Mar;53(3):536-9. Epub 2004 Jan 22.

PMID:
14739146
12.

Monitoring transplant patients for human cytomegalovirus: Diagnostic update.

Gerna G, Lilleri D.

Herpes. 2006 May;13(1):4-11. Review.

PMID:
16732996
13.

Human cytomegalovirus infection in lung transplant recipients triggers a CXCL-10 response.

Weseslindtner L, Nachbagauer R, Kundi M, Jaksch P, Kerschner H, Simon B, Hatos-Agyi L, Scheed A, Aberle JH, Klepetko W, Puchhammer-Stöckl E.

Am J Transplant. 2011 Mar;11(3):542-52. doi: 10.1111/j.1600-6143.2010.03404.x. Epub 2011 Jan 10.

14.

Systemic and local human cytomegalovirus-specific T-cell response in lung transplant recipients.

Lilleri D, Gerna G, Bruno F, Draghi P, Gabanti E, Fornara C, Meloni F.

New Microbiol. 2013 Jul;36(3):267-77. Epub 2013 Jun 30.

15.

Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.

San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM; REIPI Network.

Transpl Infect Dis. 2015 Oct;17(5):637-46. doi: 10.1111/tid.12417. Epub 2015 Aug 27.

PMID:
26134282
16.

Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.

Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.

Chest. 1999 Nov;116(5):1265-72.

PMID:
10559085
17.

Association of human cytomegalovirus DNAaemia and specific granzyme B responses in lung transplant recipients.

Weseslindtner L, Kerschner H, Steinacher D, Kundi M, Jaksch P, Simon B, Hatos-Agyi L, Scheed A, Klepetko W, Puchhammer-Stöckl E.

Clin Exp Immunol. 2013 Sep;173(3):438-43. doi: 10.1111/cei.12123.

18.

Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients.

Wéclawiak H, Kamar N, Mengelle C, Guitard J, Esposito L, Lavayssière L, Cointault O, Ribes D, Rostaing L.

J Med Virol. 2008 Jul;80(7):1228-32. doi: 10.1002/jmv.21183.

PMID:
18461614
19.

Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir.

Bounaadja L, Piret J, Goyette N, Boivin G.

J Clin Virol. 2013 Sep;58(1):279-82. doi: 10.1016/j.jcv.2013.06.024. Epub 2013 Jul 16.

PMID:
23871165
20.

Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.

Gerna G, Baldanti F, Torsellini M, Minoli L, Viganò M, Oggionnis T, Rampino T, Castiglioni B, Goglio A, Colledan M, Mammana C, Nozza F, Daniele L; Bergamo Transplant Group.

Antivir Ther. 2007;12(1):63-72.

PMID:
17503749

Supplemental Content

Support Center